Seeking Alpha

Pharmacyclics' (PCYC +1.7%) Phase III trial of its ibrutinib drug for treating leukiemia has...

Pharmacyclics' (PCYC +1.7%) Phase III trial of its ibrutinib drug for treating leukiemia has enrolled a 5th patient, thereby triggering a milestone payment of $50M from J&J (JNJ) unit Janssen Biotech. Additional $50M payments could be triggered up to a total of $250M. (PR)
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs